dc.contributor.author | Hatemi, Ibrahim | |
dc.contributor.author | Durcan, Emre | |
dc.contributor.author | Atay, Kadri | |
dc.contributor.author | Tuncer, Murat | |
dc.contributor.author | Koroglu, Emine | |
dc.contributor.author | Canbakan, Billur | |
dc.contributor.author | Yurttas, Berna | |
dc.contributor.author | Gultepe, Ilhami | |
dc.contributor.author | Ozdemir, Sebati | |
dc.contributor.author | Sonsuz, Abdullah | |
dc.date.accessioned | 2021-03-04T08:30:00Z | |
dc.date.available | 2021-03-04T08:30:00Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Atay K., Hatemi I., Canbakan B., Koroglu E., Durcan E., Yurttas B., Gultepe I., Ozdemir S., Tuncer M., Sonsuz A., "Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B", TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.27, sa.3, ss.279-283, 2016 | |
dc.identifier.issn | 1300-4948 | |
dc.identifier.other | av_639bfc44-dee2-4d50-b48a-f54d9169f5c3 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/69352 | |
dc.identifier.uri | https://doi.org/10.5152/tjg.2016.16085 | |
dc.description.abstract | Background/Aims: Several guidelines recommend the use of tenofovir or entecavir as the first-line treatment for hepatitis B due to the lower resistance rates of these drugs than lamivudine, although lamivudine may still be preferred because of its low adverse effect profile and cost. It is important to know which patients might benefit from lamivudine as the first-line treatment. We aimed to assess the success rates of lamivudine, entecavir, and tenofovir, as well as the resistance rates, frequencies of HBsAg clearance, and risk factors for lamivudine resistance. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.title | Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B | |
dc.type | Makale | |
dc.relation.journal | TURKISH JOURNAL OF GASTROENTEROLOGY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 27 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 279 | |
dc.identifier.endpage | 283 | |
dc.contributor.firstauthorID | 90489 | |